DaVita Inc. (ETR:TRL)
Germany · Delayed Price · Currency is EUR | Market Cap | 13.27B +45.7% |
| Revenue (ttm) | 12.00B +6.7% |
| Net Income | 677.72M -9.1% |
| EPS | 9.32 +6.2% |
| Shares Out | n/a |
| PE Ratio | 19.57 |
| Forward PE | 15.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 205.20 |
| Previous Close | 206.20 |
| Day's Range | 205.20 - 205.20 |
| 52-Week Range | 166.30 - 208.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About DaVita
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In... [Read more]
Financial Performance
In 2025, DaVita's revenue was $13.64 billion, an increase of 6.46% compared to the previous year's $12.82 billion. Earnings were $746.80 million, a decrease of -20.24%.
Financial numbers in USD Financial StatementsNews
DaVita price target raised to $250 from $205 at Truist
Truist raised the firm’s price target on DaVita (DVA) to $250 from $205 and keeps a Hold rating on the shares as part of a broader research note previewing Q2…
DaVita price target raised to $270 from $235 at UBS
UBS raised the firm’s price target on DaVita (DVA) to $270 from $235 and keeps a Buy rating on the shares. DaVita remains on track to achieve its long-term goal…
DaVita price target raised to $218 from $194 at Barclays
Barclays raised the firm’s price target on DaVita (DVA) to $218 from $194 and keeps an Equal Weight rating on the shares. The firm adjusted targets among its U.S. healthcare…
DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals
Kidney care leader launches its next chapter of measurable impact for patients, teammates, and communities. DENVER, May 18, 2026 /PRNewswire/ -- DaVita today announced its 2030 Community Care commitme...
DaVita Transcript: Bank of America Global Healthcare Conference 2026
Volume guidance was raised due to competitor clinic closures and improved mortality, with most benefits expected by mid-year. OI growth is supported by international and value-based care, while AI and clinical innovations are being pursued for future efficiency and patient outcomes.
DaVita price target raised to $201 from $144 at TD Cowen
TD Cowen raised the firm’s price target on DaVita (DVA) to $201 from $144 and keeps a Hold rating on the shares. The firm updated its model following Q1 results…
DaVita price target raised to $205 from $158 at Truist
Truist raised the firm’s price target on DaVita (DVA) to $205 from $158 and keeps a Hold rating on the shares. The firm is raising its assumed multiple after the…
DaVita price target raised to $235 from $190 at UBS
UBS analyst AJ Rice raised the firm’s price target on DaVita (DVA) to $235 from $190 and keeps a Buy rating on the shares.
DaVita price target raised to $194 from $158 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on DaVita (DVA) to $194 from $158 and keeps an Equal Weight rating on the shares. The firm updated the company’s…
DaVita upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Pito Chickering upgraded DaVita (DVA) to Buy from Hold with a price target of $220, up from $126, following the Q1 report. The firm sees “two shining…
DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference
DENVER, May 6, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will parti...
DaVita lifts annual profit forecast on strong demand for dialysis services
DaVita on Tuesday raised its forecast for annual adjusted profit after beating Wall Street estimates for first-quarter results, betting on steady demand for its kidney dialysis services.
DaVita Earnings Call Transcript: Q1 2026
First quarter results exceeded expectations, driven by higher treatment volume, improved productivity, and technology investments. Guidance for adjusted operating income and EPS was raised, with additional volume growth expected from competitor clinic closures.
DaVita Earnings release: Q1 2026
DaVita released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
DaVita Quarterly report: Q1 2026
DaVita has published its Q1 2026 quarterly earnings report on May 5, 2026.
DaVita reports Q1 EPS $2.87, consensus $2.33
Reports Q1 revenue $3.42B, consensus $3.36B. “DaVita’s (DVA) foundation is clinical excellence, driven by operating rigor that produces durable results,” said Javier Rodriguez, CEO of DaVita Inc. “We ...
DaVita sees FY26 adjusted EPS $14.10-$15.20, consensus $14.12
Previous guidance was $13.60-$15.00.
DaVita Inc. 1st Quarter 2026 Results
DENVER, May 5, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2026. "DaVita's foundation is clinical excellence, driven by opera...
Honeywell Announces Board of Directors for Honeywell Aerospace
Directors bring compelling mix of aerospace and defense expertise, leadership experience, and financial and capital markets backgrounds Honeywell spin-off of Honeywell Aerospace expected to be complet...
DaVita Proxy statement: Proxy filing
DaVita filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
DaVita Proxy statement: Proxy filing
DaVita filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call
DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. E...
DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement
Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy an...
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global dev...